Document text
कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय,भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)
मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली 110002
Panchdeep Bhawan,CI.G. Marg, New Delhi-110002
www.esic.gov. in, 011-23604773,dmc-rc@esic.nic.in
U-25/12/0lt_Patent/Deletion_RC_item/2025-MedV (E- 1217106)
सेवा में,
Director (Medical) Delhi/Director (Medical) Noida
Deans- AII PGIMSR's/Medical/Dental Colleges
Medical Superintendents-All ESI Hospitals
Dispensary Incharges- Delhi/NCR/States
Directors ESI Schemes- All State
Web upload
457
संशोधन सं / Corrigendum-13 in DG ESIC RC NO.162
विषयः
डीजी ईएसआईसी दर अनुबंध संख्या 162 के संबंध में शुद्धिपत्र.
Sub:Corrigendum in r/o DG-ESIC Rate Contract No. 162- reg.
संदभ: 1.) U-25/12/RC/159TO163/2022-Med.V (E-117064)/162 dtd 08.04.2025
2.) U-25/12/Off_Patent/Deletion_RC_item/2025-MedV (E- 1217106)/158 dated
05.05.2025, (console no. 20896/2025 dated 06.05.2025).
महोदय/महोदया
Reference captioned subject and in continuation to ESIC Hqrs earlier instructions vide
letter no. U-25/12/Off_Patent/Deletion_RC_item/2025-MedV (E- 1217106)/158 dated
05.05.2025 (console no. 20896/2025 dated 06.05.2025).
In this context, it is hereby informed that in the light of Clarification received from
DCGI/CDSCO and for continuing supply, the Competent Authority has revoked the de-
listing and reinstate item no. 2093 under DG ESIC RC No.162 (valid upto 07.04.2027),
as details below:
S. Name of approved
No. Pharmaceutical Firm
1.
a.) M/s Hab Pharmaceuticals &
Research Ltd:- L1 Preference
b.) M/s Unicure India Ltd:- L2
preference
c.) M/s Overseas Health Care
Private Limited:-L3 preference
RC
Ino.
Item
No.
Item Description
162
2093
Metformin + Glimepiride
Tab/Cap-Each Uncoated
Tab/Cap to contain :Metformin
Hydrochloride IP 500 mg (As a
Sustained Release,
Glimepiride IP 1mg
This is for your information and necessary action.
This issues with the approval of Competent Authority.
भवदीय
Digitally signed by
Sanjiv Kochhar
Date: 12-09-2025
13:18:20
उप चिकित्साआयुक्त (दर संविदा)
प्रतिलिपिः
1. Hab Pharmaceuticals & Research Ltd, A-301, Peninsula Business park, Ganpatrao
Kadam, MARG Lower Parel Mumbai-400013( Email:- marketing@habpharma.in.)
for information and necessary action.
2. Unicure India Ltd., C-21,22& 23, Sector-3, Noida-, Distt -Gautan Budh Nagar,
3.
4.
U.P.- 201301 (unicure@unicureindia.com,mkumar712@gmail.com) for information
and necessary action.
Overseas Health Care Private Limited, 33KM Milestone, National Highway No. 1,
P.O. Box 25, Phillaur,Jalandhar-Punjab-144410 (E-mail:
info@overseashealthcare.co.in, mohcpl@gmail.com) for information and
necessary action.
Website Content Manager with a request to upload the same on ESIC HQ website.
U-25/12/Off_Patent/Deletion_RC_item/2025-MedV
कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES'STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)
मुख्यालय / HEADQUARTERS
पंचदीप भवन, सी.आई. जी मार्ग,नई दिल्ली 110002
Panchdeep Bhawan,C.I.G. Marg. New Delh-1 10002
www.esic.gov.in 011-23604773dmc-rc@esienicin
U-25/12/Off_Patent/Deletion_RC_item/2025-MedV (E- 1217106),
सेवा में,
Director (Medical) Delhi/Director(Medical) Noida
Deans- AlI PGIMSR's/Medical/Dental Colleges
Medical Superintendents-All ESI Hospitals
Dispensary Incharges- Delhi/NCR/States
Directors ESI Schemes- All State
Dated:
1158
संशोधन सं /Corrigendum-06 in DG ESIC RC NO. 162
विषय: Corrigendum in r/o DG-ESIC Rate Contract No.162- reg.
संदर्भ:U-25/12/RC/159TO163/2022-Med.V (E-117064)/162 dtd 08.04.2025
Sir/Madam
Reference captioned subject, it is hereby informed that following below
mention drugs/items have been deleted from the approved item list of DG-ESIC Central
Rate Contract No.162 (valid from 08.04.2025 to 07.04.2027) :
A)
S. Name of approved
Item Item Description
Preference Remarks
No. Pharmaceutical Firm
No.
1
M/s Boehringer
Ingelheim India
Private Limited
2094 Empagliflozin Tab/Cap Each film
coated tab/cap to contain:
Empagliflozin 10 mg
Brand Name-(Jardiance 10
mg)
1st
Off-
PreferencelPatent
2
M/s Boehringer
Ingelheim India
Private Limited
2231 Empagliflozin + Linagliptin-
Each Tab/Cap to contain:
Empagliflozin 10 mg +
1st
PreferenceF
Off-
Patent
Linagliptin 5 mg
Brand Name- GLYXAMBI®
5/10 mg
1/2507661/2025
U-25/12/Off_Patent/Deletion_RC_item/2025-MedV
Contd. to pre-page:-
B)
S. Name of approved
No. Pharmaceutical Firm with
preference
Item
No.
Item Description
Remarks
1
a. M/s Hab
Pharmaceuticals &
Research Ltd:- L1
preference
b. M/s Unicure India Ltd:-
L2 preference
C. M/s Overseas Health
Care Private Limited:-
L3 preference
2093 Metformin +
Glimepiride Tab/Cap-
Each Uncoated
Tab/Cap to contain:
Metformin
Hydrochloride IP 500
mg (As a Sustained
Release, Glimepiride
IP 1mg.
This is for your information and necessary action.
This issues with the approval of Competent Authority.
Withdrawal/Cancellation
of FDC Approval by
CDSCO
Copy to:
Yours Sincerely
Digitally signed by
Sanjiv Kochhar
Date: 05-05-2025
Deputy Medical CaiAsoner (RC)
1. M/s Boehringer Ingelheim India Private Limited, Unit No. 202 and part of Unit
no.201, 2nd Floor Godrej 2, Pirojsha Nagar, Eastern express Highway, Vikhroli (E),
Mumbai-400079
(Email-pmibtender.in@boehringer-ingelheim.com,
anurag.sharma@ boehringer-ingelheim.com, prerana.yadav@boehringer-
ingelheim.com) for information.
2. Hab Pharmaceuticals & Research Ltd, A-301, Peninsula Business park, Ganpatrao
Kadam, MARG Lower Parel Mumbai-400013( Email:- marketing@habpharma.in.)
for information.
3.
4.
Unicure India Ltd., C-21,22& 23, Sector-3, Noida-, Distt -Gautan Budh Nagar,
U.P.- 201301 (unicure@unicureindia.com, mkumar712@gmail.com) for
information.
Overseas Health Care Private Limited, 33KM Milestone, National Highway No. 1,
P.O.
Box
25, Phillaur,Jalandhar-Punjab-144410 (E-mail:
info@overseashealthcare.co.in, dmohcpl@gmail.com) for information.
5. Website Content Manager with a request to upload the same on ESIC HQ website.
1/2507661/2025
